Research programme: antibacterial potentiator therapeutics - Spero Therapeutics

Drug Profile

Research programme: antibacterial potentiator therapeutics - Spero Therapeutics

Alternative Names: Potentiator programme - Spero

Latest Information Update: 23 Jun 2016

Price : $50

At a glance

  • Originator Northern Antibiotics
  • Developer Evotec AG; Spero Therapeutics
  • Class Antibacterials; Peptides; Small molecules
  • Mechanism of Action Bacterial outer membrane protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gram-negative infections; Intra-abdominal infections; Urinary tract infections

Most Recent Events

  • 20 Jun 2016 Preclinical trials in Gram-negative infections in USA (unspecified route)
  • 08 Jun 2016 Spero Therapeutics plans a clinical trial for Gram-negative infections
  • 15 Dec 2015 Spero Therapeutics and Evotec AG agree to co-develop antibacterial potentiator therapeutics for Gram-negative infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top